Fed Circ. Rejects Amgen Bid For DNA Patent

Law360, New York (April 3, 2009, 12:00 AM EDT) -- In a decision that raises the bar for biotechnology companies to protect their work on DNA sequencing, Amgen Inc. has lost a federal appeals court fight to obtain a patent related to so-called natural killer cells in bone marrow.

In a widely watched case, the U.S. Court of Appeals for the Federal Circuit on Friday upheld the U.S. Patent and Trademark Office's rejection of the application by two Amgen scientists — Marek Z. Kubin and Raymond G. Goodwin — for a patent related to sequencing a...
To view the full article, register now.